MOTS-c Dosage Protocol: Injection Frequency, Cycling, and Stacking with NAD+ (2026)

What Is MOTS-c?

MOTS-c is a 16-amino-acid peptide encoded inside your mitochondrial DNA rather than your nuclear genome, first identified in 2015 and studied since as an exercise-mimetic metabolic regulator. It activates AMPK, the same energy-sensing switch your body flips during training, which is why researchers frame it as a way to trigger exercise-like metabolic signaling pharmacologically.

MOTS-c stands for mitochondrial open reading frame of the 12S rRNA-c. It is one of a small family of mitochondrial-derived peptides your cells produce naturally, and it behaves less like a hormone and more like a messenger that travels from your mitochondria back to your cell nucleus to switch on stress-adaptation genes. The foundational work identifying this mechanism showed MOTS-c regulates insulin sensitivity and prevents diet-induced obesity in animal models by activating AMPK, the same pathway exercise engages (Lee 2016).

The peptide is conserved across at least 14 species, which tells you the pathway it controls is ancient and fundamental rather than a evolutionary accident. In human tissue, MOTS-c expression rises in skeletal muscle and blood after exercise, and levels are documented to fall with age and with metabolic disease, correlating with reduced insulin sensitivity and lower exercise capacity (Zheng 2023). That age-related decline is the core argument behind supplementing it: if your endogenous MOTS-c drops off as you get older, restoring it might restore some of the metabolic flexibility that goes with it.

Mechanistically, MOTS-c drives its effects through what is called the Folate-AICAR-AMPK pathway. AICAR is a molecule that accumulates and directly activates AMPK, which then reaches into the nucleus to change how hundreds of stress-response and metabolic genes are expressed (Wan 2023). Downstream of that, MOTS-c improves glucose uptake in skeletal muscle by promoting GLUT4 transporter movement to the cell surface, which is the same mechanism that makes a hard training session improve your insulin sensitivity for the following 24 to 48 hours.

MOTS-c Dosage Protocol: Starting Dose and Titration

A typical MOTS-c dosage protocol starts at 2.5 to 5 mg subcutaneously, three times weekly, titrated upward over four to six weeks to a maintenance range of 5 to 10 mg, three to five times weekly. These figures come from anecdotal reports across the research and biohacking community rather than a completed human dosing trial, so treat them as a starting reference, not a fixed prescription.

It matters to be direct about where these numbers actually come from. The only completed human trial in this space used CB4211, a MOTS-c analog rather than native MOTS-c, dosed at 25 mg per day subcutaneously for four weeks in obese patients with fatty liver disease. Native MOTS-c dosing protocols circulating in the recovery and biohacking space are extrapolated from that trial, from rodent metabolic studies using weight-based dosing, and from user-reported anecdotal experience. There is no completed Phase 2 or 3 trial establishing an optimal human dose for native MOTS-c.

With that caveat stated plainly, the practical pattern most people follow looks like this: start low for the first one to two weeks to assess individual tolerance, then step up gradually. A conservative titration schedule runs 2.5 mg three times weekly for two weeks, then 5 mg three times weekly for two to four weeks, before considering a move to 5 to 10 mg administered three to five times weekly if metabolic markers and tolerance support it. Always work with a qualified clinician before making changes to your health protocol, particularly one involving an unregulated, non-FDA-approved peptide.

Injection Frequency: How Often to Inject MOTS-c

Most MOTS-c protocols use three to five subcutaneous injections per week rather than a single weekly dose, because the peptide's half-life is short and its metabolic signaling effect appears to be more consistent with repeated, closely spaced dosing rather than one large weekly bolus.

Subcutaneous injection is the only clinically relevant route. Oral MOTS-c is broken down by gastrointestinal enzymes before it ever reaches circulation, and there is no viable oral formulation on the market or in development that overcomes this. That leaves subcutaneous injection, typically into the abdomen or thigh, as the standard delivery method reported across research and biohacking communities.

On timing within the day, the most common pattern reported is a morning injection, 30 to 60 minutes ahead of a training session, on the logic that MOTS-c and exercise both converge on AMPK activation, so stacking the two close together may compound the metabolic signal. If you are sensitive to blood sugar fluctuations, injecting in a fasted state is worth monitoring closely rather than assuming it will feel the same as a fed-state injection.

Cycling MOTS-c: Cycle Length and Washout Periods

There is no published human evidence defining an optimal MOTS-c cycle length. Common practice in the research and biohacking space runs four to twelve week cycles followed by a washout period, based on general peptide-cycling logic rather than data specific to MOTS-c desensitization or receptor downregulation.

The reasoning behind cycling rather than continuous use is precautionary. AMPK activation is a powerful signaling pathway, and chronic, uninterrupted activation of any metabolic switch carries a theoretical risk of blunted responsiveness over time, the same concern that drives cycling logic in other AMPK-adjacent compounds. Because this has not been studied directly for MOTS-c in humans, a conservative approach: run a defined cycle, take a break of similar or longer length, and reassess biomarkers before resuming, is the sensible default rather than continuous daily use indefinitely.

Stacking MOTS-c with NAD+

MOTS-c and NAD+ target complementary parts of the same mitochondrial system: MOTS-c activates AMPK to switch on metabolic and stress-adaptation gene expression, while NAD+ supplies the substrate sirtuins need to drive mitochondrial biogenesis and cellular repair. Stacking the two is a common pattern in metabolic-health-focused research protocols.

Recent preclinical work adds a specific mechanistic link between the two: MOTS-c treatment in aged pancreatic islet cells increased NAD+ levels and reduced markers of cellular senescence, alongside improved glucose tolerance in aged mouse models (MOTS-c and pancreatic beta-cell senescence, 2025). That finding suggests MOTS-c and NAD+ are not just complementary in theory but may interact directly at the cellular level, particularly around age-related metabolic decline.

Practically, most people running this stack administer MOTS-c subcutaneously on the same schedule described above, and layer in NAD+ through their preferred route, whether that is subcutaneous injection, IV, or an oral precursor like NMN or NR. There is no published human trial testing the two compounds together, so the rationale here is mechanistic plausibility rather than confirmed synergy.

What the Human Trial Data Actually Shows

Human data on MOTS-c itself is thin. The only completed human trial used CB4211, a MOTS-c analog, not native MOTS-c: a Phase 1a safety study in 65 healthy adults followed by a Phase 1b efficacy study in 20 obese patients with fatty liver disease, dosed at 25 mg per day subcutaneously for four weeks.

That Phase 1b trial reported meaningful reductions in liver enzymes, ALT down roughly 21 percent and AST down roughly 28 percent, alongside a decrease in blood glucose relative to placebo, with no serious adverse events reported across either study arm. That is a genuinely encouraging early signal for a MOTS-c-based compound, but it is an analog molecule in a small, short trial, not a validation of native MOTS-c dosing protocols circulating in the research community.

Separately, preclinical work has extended MOTS-c's mechanism beyond metabolism into cardiac tissue repair. In a rat model of diabetic heart dysfunction, daily MOTS-c injection restored mitochondrial bioenergetic function and contractile performance over three weeks (Pham 2025), and separate in vitro and in vivo work has shown MOTS-c helps repair damaged cell membranes during ischemia and reperfusion stress by interacting with the membrane-repair protein TRIM72 (Jia 2024). These are preclinical, animal-model findings, not human trial evidence, and should be read as mechanistic support for the compound's biology rather than proof of human clinical benefit.

Safety, Side Effects, and Regulatory Status

MOTS-c has no FDA approval and no completed Phase 2 or later human trial. It is also banned by WADA under the 2024 Prohibited List as an AMPK activator, with no therapeutic use exemption available, so if you compete under WADA jurisdiction, MOTS-c is off the table entirely.

On the CB4211 analog trial, the reported side effect profile was mild: localized injection site reactions such as redness, itching, and discomfort, with no serious adverse events across either study phase. Anecdotal reports in the broader biohacking community mention heart palpitations and elevated heart rate with native MOTS-c use, but these are unverified user reports rather than data from a published safety study, and they should be weighed accordingly.

The bigger unknown is long-term human safety. There is no chronic-use human data for native MOTS-c, no established safe upper dosing threshold, and no data on what happens to endocrine or immune markers with sustained AMPK activation over months or years. If you decide to research this compound, baseline bloodwork, fasting glucose, HbA1c, insulin, a lipid panel, and liver enzymes, gives you something concrete to track rather than going in blind. Always work with a qualified clinician before making changes to your health protocol.

Sourcing MOTS-c: What to Check Before You Buy

Because MOTS-c sits entirely outside FDA oversight, product quality varies enormously between suppliers, and third-party purity and identity testing is the single most important check you can run before using any batch. A certificate of analysis from an independent lab is the baseline, not a nice-to-have.

Peptides sold outside a licensed compounding pharmacy carry no regulatory guarantee of purity, concentration, or even correct identity. If you are researching where to source MOTS-c, see our recommended sources page for a vendor-neutral overview of what third-party testing and documentation to look for before you commit to a supplier. If you're researching this compound, I've linked a trusted source below. It supports the channel.

For a broader look at how to vet peptide purity claims and read a certificate of analysis properly, our guide on how to know if peptides are real walks through the specific red flags to check for before you buy. And if you are comparing MOTS-c against other metabolic and growth-axis peptide protocols, our tesamorelin dosage protocol breakdown covers a related, better-studied dosing framework for context.

References

Lee C, et al. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. PubMed.

Wan T, et al. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. PMC.

Zheng D, et al. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. PMC.

Pham T, et al. Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart. PMC.

Jia D, et al. Mitochondria-encoded peptide MOTS-c participates in plasma membrane repair by facilitating the translocation of TRIM72. PMC.

Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes, Experimental & Molecular Medicine, 2025. Nature.

CohBar Announces Positive Topline Results from Phase 1a/1b Study of CB4211. GlobeNewswire.

This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. Always work with a qualified clinician before making changes to your health protocol.